IMPRINT Radiation Therapy for Thymic Cancer
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. However, if you are on chronic oral steroid therapy for COPD, you may not be eligible to participate.
Research shows that intensity-modulated pleural radiation therapy (IMPRINT) has been effective in treating malignant pleural mesothelioma, a type of cancer affecting the lining of the lungs, by improving tumor control and reducing side effects compared to older methods. This suggests that IMPRINT could potentially be effective for thymic cancer as well, given its success in similar conditions.
12345IMPRINT radiation therapy has been studied for safety in conditions like malignant pleural mesothelioma and thymoma. The studies show that it meets safety standards for organs like the lungs, heart, and esophagus, with low complication probabilities, indicating it is generally safe for humans.
12567IMPRINT treatment is unique because it uses advanced radiation techniques to target the pleura (the lining of the lungs) while sparing the lung itself, which may reduce damage to nearby organs like the heart and esophagus compared to conventional radiation therapies.
23789Eligibility Criteria
This trial is for adults aged 18-80 with thymic cancer that has spread to the lung and chest lining but not beyond. Participants must be in good physical condition, have a certain level of lung and kidney function, and cannot be pregnant or breastfeeding. They must agree to use contraception and have no history of severe lung disease, recent heart failure, or specific treatments like thoracic radiation.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) over approximately 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including progression-free survival and radiation pneumonitis
Participant Groups
Intensity-Modulated Pleural Radiation Therapy (IMPRINT) is already approved in United States, European Union, Japan for the following indications:
- Thymic cancer with pleural metastases
- Thymic malignancies with pleural dissemination
- Thymic carcinoma with pleural metastases